Wei Guo1, Ximin Fan2, Bradley R Lewis3, Matthew P Johnson3, Charanjit S Rihal4, Amir Lerman4, Joerg Herrmann5. 1. Department of Emergency Medicine, Peking University People's Hospital, Beijing, China. 2. Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. 3. Section of Biostatistics, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. 5. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: herrmann.joerg@mayo.edu.
Abstract
OBJECTIVES: This study sought to define the risk of stent thrombosis (ST) and myocardial infarction (MI) in cancer patients compared with noncancer patients after percutaneous coronary intervention (PCI). BACKGROUND: Cancer patients are considered to be at high thrombotic risk, but data on whether this is the case after PCI remain inconclusive. METHODS: Cancer patients undergoing PCI at Mayo Clinic Rochester from January 1, 2003, to December 31, 2013, were identified by cross-linking institutional cancer and PCI databases and by propensity score matching to noncancer patients. The combined primary endpoint was all-cause mortality, MI, and revascularization rate at 5-year follow-up. Secondary endpoints were the individual primary endpoint components, cause of mortality, ST, and Bleeding Academic Research Consortium 2+ bleeding. RESULTS: The primary endpoint occurred in 48.6% of 416 cancer and in 33.0% of 768 noncancer patients (p < 0.001). In competing risk analyses, cancer patients had a higher rate of noncardiac death (24.0% vs. 10.5%; p < 0.001) and a lower rate of cardiac death (5.0% vs. 11.7%; p < 0.001). Cancer patients had a higher rate of MI (16.1% vs. 8.0%; p < 0.001), ST (6.0% vs. 2.3%; p < 0.001), repeat revascularization (21.2% vs. 10.0%; p < 0.001), and bleeding (6.7% vs. 3.9%; p = 0.03). The most critical period for ST in cancer patients was in the first year after PCI. The dual antiplatelet therapy score was predictive of thrombotic and ischemic events in both groups. CONCLUSIONS: Cancer patients have a higher risk of thrombotic and ischemic events after PCI, identifiable by a high dual antiplatelet therapy score. These findings have important implications for antiplatelet therapy decisions.
OBJECTIVES: This study sought to define the risk of stent thrombosis (ST) and myocardial infarction (MI) in cancer patients compared with noncancer patients after percutaneous coronary intervention (PCI). BACKGROUND: Cancer patients are considered to be at high thrombotic risk, but data on whether this is the case after PCI remain inconclusive. METHODS: Cancer patients undergoing PCI at Mayo Clinic Rochester from January 1, 2003, to December 31, 2013, were identified by cross-linking institutional cancer and PCI databases and by propensity score matching to noncancer patients. The combined primary endpoint was all-cause mortality, MI, and revascularization rate at 5-year follow-up. Secondary endpoints were the individual primary endpoint components, cause of mortality, ST, and Bleeding Academic Research Consortium 2+ bleeding. RESULTS: The primary endpoint occurred in 48.6% of 416 cancer and in 33.0% of 768 noncancer patients (p < 0.001). In competing risk analyses, cancer patients had a higher rate of noncardiac death (24.0% vs. 10.5%; p < 0.001) and a lower rate of cardiac death (5.0% vs. 11.7%; p < 0.001). Cancer patients had a higher rate of MI (16.1% vs. 8.0%; p < 0.001), ST (6.0% vs. 2.3%; p < 0.001), repeat revascularization (21.2% vs. 10.0%; p < 0.001), and bleeding (6.7% vs. 3.9%; p = 0.03). The most critical period for ST in cancer patients was in the first year after PCI. The dual antiplatelet therapy score was predictive of thrombotic and ischemic events in both groups. CONCLUSIONS: Cancer patients have a higher risk of thrombotic and ischemic events after PCI, identifiable by a high dual antiplatelet therapy score. These findings have important implications for antiplatelet therapy decisions.
Authors: S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil Journal: J Clin Epidemiol Date: 2001-04 Impact factor: 6.437
Authors: Babak B Navi; Anne S Reiner; Hooman Kamel; Costantino Iadecola; Peter M Okin; Scott T Tagawa; Katherine S Panageas; Lisa M DeAngelis Journal: Blood Date: 2018-12-21 Impact factor: 22.113
Authors: Katherine H Chau; Ajay J Kirtane; Rachel M Easterwood; Björn Redfors; Zixuan Zhang; Bernhard Witzenbichler; Giora Weisz; Thomas D Stuckey; Bruce R Brodie; Michael J Rinaldi; Franz-Josef Neumann; D Christopher Metzger; Timothy D Henry; David A Cox; Peter L Duffy; Ernest L Mazzaferri; Roxana Mehran; Gregg W Stone Journal: JACC Cardiovasc Interv Date: 2021-01-19 Impact factor: 11.195
Authors: Babak B Navi; Anne S Reiner; Hooman Kamel; Costantino Iadecola; Peter M Okin; Mitchell S V Elkind; Katherine S Panageas; Lisa M DeAngelis Journal: J Am Coll Cardiol Date: 2018-01-16 Impact factor: 24.094
Authors: Feilong Wang; Rajiv Gulati; Ryan J Lennon; Bradley R Lewis; Jae Park; Gurpreet S Sandhu; R Scott Wright; Amir Lerman; Joerg Herrmann Journal: Mayo Clin Proc Date: 2016-12 Impact factor: 7.616
Authors: Robert W Yeh; Eric A Secemsky; Dean J Kereiakes; Sharon-Lise T Normand; Anthony H Gershlick; David J Cohen; John A Spertus; Philippe Gabriel Steg; Donald E Cutlip; Michael J Rinaldi; Edoardo Camenzind; William Wijns; Patricia K Apruzzese; Yang Song; Joseph M Massaro; Laura Mauri Journal: JAMA Date: 2016-04-26 Impact factor: 56.272
Authors: Matthijs A Velders; Helèn Boden; Sjoerd H Hofma; Susanne Osanto; Bas L van der Hoeven; Anton A C M Heestermans; Suzanne C Cannegieter; J Wouter Jukema; Victor A W M Umans; Martin J Schalij; Adrianus J van Boven Journal: Am J Cardiol Date: 2013-09-21 Impact factor: 2.778
Authors: Yasushi Ueki; Benjamin Vögeli; Alexios Karagiannis; Thomas Zanchin; Christian Zanchin; Daniel Rhyner; Tatsuhiko Otsuka; Fabien Praz; George C M Siontis; Christina Moro; Stefan Stortecky; Michael Billinger; Marco Valgimigli; Thomas Pilgrim; Stephan Windecker; Thomas Suter; Lorenz Räber Journal: JACC CardioOncol Date: 2019-12-17